Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Magnetic resonance outcome measures in multiple sclerosis trials: time to rethink?
An expanded composite scale of MRI-defined disease severity in multiple sclerosis: MRDSS2.
Modeling Linkage Disequilibrium Increases Accuracy of Polygenic Risk Scores.
Myeloid cell-based therapies in neurological disorders: How far have we come?
Serum neurofilament light chain in early relapsing remitting MS is increased and correlates with CSF levels and with MRI measures of disease severity.
Increased S-nitrosothiols are associated with spinal cord injury in multiple sclerosis.
Efficacy and safety of fingolimod (FTY720) in patients with relapsing-remitting multiple sclerosis (FREEDOMS II)
Serum uric acid levels and their correlation with clinical and cerebrospinal fluid parameters in patients with neuromyelitis optica.
Exercise barriers and preferences among women and men with multiple sclerosis.
Traumatic injury and multiple sclerosis: a systematic review and meta-analysis.
Contribution of cortical and white matter lesions to cognitive impairment in multiple sclerosis.
Vaccine against autoimmune disease: can helminths or their products provide a therapy?
New markers of early cardiovascular risk in multiple sclerosis patients: Oxidized-LDL correlates with clinical staging.
Transcription factor-mediated reprogramming of fibroblasts to expandable, myelinogenic oligodendrocyte progenitor cells.
Increased thyroid autoimmunity among women with multiple sclerosis in the postpartum setting.
The innate immune system in demyelinating disease.
Fampridine improves severe dysarthria in secondary-progressive multiple sclerosis.
Effectiveness of telerehabilitation interventions in persons with multiple sclerosis: A systematic review.
Systemic Injection of Low-Dose Lipopolysaccharide Fails to Break down the Blood-Brain Barrier or Activate the TLR4-MyD88 Pathway in Neonatal Rat Brain.
Age-related Shift in Neural Complexity Related to Task Performance and Physical Activity.
Demyelinating encephalopathy in adult onset Still's disease: Case report and review of the literatures.
Long-term effects of whole body cryostimulation on uric acid concentration in plasma of secondary progressive multiple sclerosis patients.
Optic coherence tomography findings in relapsing-remitting multiple sclerosis patients of the northwest of Iran.
Multiple sclerosis is associated with psoriasis. A case-control study.
Tregitope Peptides: The Active Pharmaceutical Ingredient of IVIG?
Pages
« first
‹ previous
…
467
468
469
470
471
472
473
474
475
…
next ›
last »